Interestingly, it was also found that viral antigen could persist between 120C150 days in the tissues of mice that had their B cells depleted prior to challenge and that those mice who additionally had their CD4+ T cells depleted the magnitude of viral antigen that persisted was increased (48). have emerged from animal models, studies in survivors and vaccine clinical trials and explains how these investigations have helped in the search for a correlate of protection. Keywords: Ebolavirus, correlate of protection, animal models, survivors, vaccine Introduction Ebolavirus belongs to the family and consists of six characterized species; Bundibugyo (BDBV), Reston (RESTV), Sudan (SUDV), Ta? Forest (TAFV), Zaire (EBOV) and the recently described Bombali (BOMV) (1) (2). The EBOV species is commonly regarded as being the most pathogenic (3) and is the focus of this review. EBOV consists of 7 proteins; L-protein (L), Virion protein (VP) GSK1904529A 40, VP24, VP30, VP35, Glycoprotein (GP), and Nucleoprotein (NP) (4) as shown in Figure 1A . The virion is enveloped by membrane GP and the genome is non-segmented, with proteins encoded for by negative single-stranded RNA (-ssRNA) (4). The GP, which resides in the viral envelope, is the primary focus of much vaccine research as it is responsible for binding to the host cell and mediating cell entry. Therefore, antibodies to the GP are critical to antibody mediated neutralisation (1). NP is the major component of the nucleocapsid along with VP35 and VP24. VP40 is the matrix protein essential for budding of new virions. The RNA-dependent RNA polymerase L and the polymerase cofactor VP35 facilitate genome replication and transcription. VP30 is a component of the nucleocapsid and a transcription factor (5, 6). Typically, following attachment, EBOV will be macropinocytosed by the host cell and will escape the resulting lysosome binding to Niemen Pick C1 receptor (NPC1) on the endosome membrane. This interaction results in the release of viral product into the host cell cytoplasm (7). The genome is then transcribed into seven mRNAs by the viral polymerase which consists of L protein and VP35; these products are then translated by host cell machinery. The increase in viral protein eventually results in a switch to produce and package -ssRNA. Viral proteins converge at the host cell surface where they are packaged and bud from the cell resulting in viral progeny and GSK1904529A ultimately cell death (7). Open in a separate window Figure 1 (A) Structural proteins of EBOV. EBOV is composed of seven structural proteins: L-protein (L), Virion protein GSK1904529A (VP) 40, VP24, VP30, VP35, Glycoprotein (GP), and Nucleoprotein (NP). GP is exposed on the viral envelope. It mediates host cell attachment and cell entry. The nucleocapsid is composed of NP, VP35, and VP24. NP binds the viral genome. The polymerase L and its cofactor VP35 drive genome replication and transcription. VP30 is a transcription factor which is also a component of the nucleocapsid. (B) Genomic structure of EBOV and genetic segments targeted for vaccines. Genes encoding for each structural protein are shown. Interestingly, the GP gene also encodes for soluble GP (sGP) and small soluble GP Rabbit Polyclonal to PLA2G4C (ssGP). Licensed vaccines (rVSV-ZEBOV, Ad26.ZEBOV) and most candidate vaccines (ChAd3-EBO-Z, RNA and DNA vaccines) use GP as antigen because antibody responses following a natural infection mainly target GP. Other antigens such as NP or VP40 have been also evaluated in the licensed MVA-BN-Filo and some candidate peptide or virus-like particle (VLP)-based vaccines. Figure created with BioRender.com. EBOV was first classified in 1976 following an outbreak of viral haemorrhagic disease in the Democratic Republic of Congo (DRC), formally Zaire. This outbreak is thought to have originated in a missionary hospital in GSK1904529A the village of Yambuku (8C10). Initial blood samples were sent to the Institute of Tropical Medicine (ITM; Antwerp, Belgium) where a Marburg-like virus was identified by electron microscopy (10). Samples were then sent to the Microbiological Research Establishment (Porton Down, UK) and Centres for.